Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy
Kim, R., Kwon, M., An, M., Kim, S.T., Smith, S.A., Loembé, A.B., Mortimer, P.G.S., Armenia, J., Lukashchuk, N., Shah, N., Dean, E., Park, W.-Y., Lee, J.
Published in Annals of oncology (01.02.2022)
Published in Annals of oncology (01.02.2022)
Get full text
Journal Article
A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma
Palmer, D. H., Ma, Y. T., Peck-Radosavljevic, M., Ross, P., Graham, J., Fartoux, L., Deptala, A., Studeny, M., Schnell, D., Hocke, J., Loembé, A-B., Meyer, T.
Published in British journal of cancer (01.05.2018)
Published in British journal of cancer (01.05.2018)
Get full text
Journal Article
A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results
Eisen, T, Loembé, A-B, Shparyk, Y, MacLeod, N, Jones, R J, Mazurkiewicz, M, Temple, G, Dressler, H, Bondarenko, I
Published in British journal of cancer (20.10.2015)
Published in British journal of cancer (20.10.2015)
Get full text
Journal Article
PD-005 Combined analysis of two randomised Phase II trials comparing the efficacy and safety of nintedanib versus sorafenib in Caucasian and Asian patients with advanced hepatocellular carcinoma
Palmer, D., Meyer, T., Chao, Y., Deptala, A., Fartoux, L., Feng, Y.-H., Graham, J., Lin, D.-Y., Ma, Y.T., Peck-Radosavljevic, M., Ross, P., Ryoo, B.-Y., Yen, C.-J., Hocke, J., Vlassak, S., Wenz, A., Loembe, A.-B., Cheng, A.-L.
Published in Annals of oncology (01.06.2015)
Published in Annals of oncology (01.06.2015)
Get full text
Journal Article